Is biotech taking a trip to the world of psychedelic drugs? Why is Novo Nordisk going after Eli Lilly’s Zepbound ads? | This week on “The Top Line,” Fierce’s Zoey Becker, Will Maddox and Kevin Dunleavy break down a major psychedelics acquisition, a politically charged peptide adcomm and the latest legal clash between the obesity drug giants.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s…
Novo Nordisk sues Eli Lilly over GLP-1s, Medicare pricing plans, and more biotech news from The Readout
This week on “The Top Line,” Fierce Healthcare and Life Sciences’ editor-in-chief steps behind the microphone for a solo episode…
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and…
Novo Nordisk is escalating its legal battle against Eli Lilly over its GLP-1 drug marketing, notifying a federal court that it…
